Covestor LTD Exelixis, Inc. Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Covestor LTD holds 6,335 shares of EXEL stock, worth $225,589. This represents 0.1% of its overall portfolio holdings.

Number of Shares

6,335

Previous 5,994 5.69%

Holding current value

$225,589

Previous $135,000 21.48%

% of portfolio

0.1%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$21.96 - $27.6 $7,488 - $9,411	341 Added 5.69%	6,335 $164,000
Q2 2024 Aug 09, 2024	SELL	$20.34 - $23.73 $24,896 - $29,045	-1,224 Reduced 16.96%	5,994 $135,000
Q1 2024 May 10, 2024	BUY	$20.17 - $23.93 $41,146 - $48,817	2,040 Added 39.4%	7,218 $171,000
Q4 2023 Feb 09, 2024	SELL	$19.25 - $24.13 $34,996 - $43,868	-1,818 Reduced 25.99%	5,178 $124,000
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $23,571 - $28,152	1,238 Added 21.5%	6,996 $153,000
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $151,138 - $170,352	-8,318 Reduced 59.09%	5,758 $110,000
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $23,716 - $28,241	1,455 Added 11.53%	14,076 $273,000
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $47,767 - $55,526	3,193 Added 33.87%	12,621 $202,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $107,988 - $153,373	6,887 Added 271.04%	9,428 $148,000
Q2 2022 Aug 10, 2022	BUY	$17.44 - $23.16 $15,085 - $20,033	865 Added 51.61%	2,541 $53,000
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $20,282 - $26,999	1,191 Added 245.57%	1,676 $38,000
Q4 2021 Feb 10, 2022	BUY	$15.84 - $21.88 $7,682 - $10,611	485 New	485 $9,000

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account